Clinical Trial Update: A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating BRIA-OTS Cellular Immunotherapy for metastatic recurrent breast cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• BRIA-OTS

Snippet

Sponsor: BriaCell Therapeutics Corporation | Conditions: Breast Cancer, Breast Tumor | Phase 1, Phase 2 | Status: RECRUITING